BioWorld

Jan. 21, 2019

View Archived Issues

Money raised by biotech: 2019 vs. 2018

Biopharma money raised: Jan. 1 - 17, 2019

Week in review

Week in Washington

Word on the street

Conference data: December 2018

Regulatory submissions, approvals and other actions: December 2018

Handing over the dealmaking torch, 2018 logs monster biopharma deals, paves the way for top M&As

Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave. Read More

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...